Is ImmunityBio Inc. (IBRX) The Best US Stock To Buy Under $20?

ImmunityBio Inc. (NASDAQ:IBRX) is among the best US stocks to buy under $20. As of November 26, ImmunityBio Inc. (NASDAQ:IBRX) is a consensus Buy, with all analysts covering it assigning a Buy or equivalent rating. With a consensus 1-year median price target of $8, the stock has an upside of over 275%.

On November 13, Jason Kolbert, an analyst at D. Boral Capital, reaffirmed his ‘Buy’ rating on ImmunityBio, Inc., with an unchanged price target of $24. This stance is in line with the analyst’s previous rating on November 5, 2025.

Photo by National Cancer Institute on Unsplash

During the recent quarter, ImmunityBio, Inc. reported a substantial increase in revenue, thanks to the commercial distribution of ANKTIV A, its lead product targeting non-muscle-invasive bladder cancer. With total revenue of $75 million for the nine months ended September 30, the company impressively surpassed the $7.2 million level in the same period in 2024.

Although revenue growth stole the spotlight, ImmunityBio, Inc. found itself in the middle of financial challenges, having reported a net loss of $289.5 million for the nine-month period. Much of this loss is due to the company’s operating expenses, primarily R&D outflows. Throughout the earnings call, management highlighted its focus on ANKTIV A’s market expansion and development of immunotherapy and cell therapy products.

ImmunityBio, Inc. is a California-based commercial-stage biotechnology company that engages in therapies to combat cancers and infectious diseases. With a mission to “conquer cancer,” the company leverages its collaborations with the National Cancer Institute, Serum Institute of India Private Limited, and BeiGene, Ltd.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.